Weight issues for people with epilepsy—A review
- 29 November 2007
- Vol. 48 (s9), 42-45
- https://doi.org/10.1111/j.1528-1167.2007.01402.x
Abstract
Weight gain or loss is not an integral part of epilepsy although a sedentary lifestyle can contribute to weight gain. Pharmacological treatment for epilepsy may be associated with substantial weight changes that may increase morbidity and impair adherence to the treatment regimen. Antiepileptic drugs (AEDs) associated with weight loss are felbamate, topiramate, and zonisamide. AEDs associated with weight gain are gabapentin, pregabalin, valproic acid, and vigabatrin and possibly, carbamazepine. Weight neutral AEDs are lamotrigine, levetiracetam, and phenytoin. In clinical practice it is critical to weigh patients regularly and AED selection should be based on each patient's profile without sacrificing therapeutic efficacy.Keywords
This publication has 20 references indexed in Scilit:
- Randomized dose-controlled study of topiramate as first-line therapy in epilepsyActa Neurologica Scandinavica, 2005
- Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsyNeurology, 2005
- Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial SeizuresEpilepsia, 2003
- Predictors of Weight Loss in Adults with Topiramate‐Treated EpilepsyObesity Research, 2003
- A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxisNeurology, 2002
- Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizuresNeurology, 2001
- The long-term use of felbamate in children with severe refractory epilepsyEpilepsy Research, 2001
- Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsyNeurology, 2001
- Stable weight during lamotrigine therapy: A review of 32 studiesNeurology, 2000
- Changes in Body Weight With Chronic, High-Dose Gabapentin TherapyTherapeutic Drug Monitoring, 1997